tracken
Amarin Corporation Plc Sponsored ADR Aktie News
Neutral
Seeking Alpha
●
etwa 24 Stunden alt
Amarin Corporation plc (NASDAQ:AMRN ) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Patrick Holt – President and Chief Executive Officer Jonathan Provoost – Chief Legal and Compliance Officer Steve Ketchum – President-R&D and Chief Scientific Officer Tom Reilly – Chief Financial Officer ...
Neutral
GlobeNewsWire
●
ein Tag alt
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK--
Neutral
GlobeNewsWire
●
8 Tage alt
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients
Neutral
GlobeNewsWire
●
10 Tage alt
- Shareholders Approve Share Repurchase Program of up to $50 Million - - Shareholders Approve Share Repurchase Program of up to $50 Million -
Neutral
GlobeNewsWire
●
17 Tage alt
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET.
Neutral
GlobeNewsWire
●
24 Tage alt
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
Neutral
GlobeNewsWire
●
26 Tage alt
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) –
Positiv
The Motley Fool
●
29 Tage alt
Amarin's Vazkepa notched a crucial win with a European regulator. The medication earned an extension to its patent exclusivity on that market.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
